For the nine months ended September 30, 2012, revenue for BEST was $98.4 million, an increase of 23.3% compared to $79.8 million in the first nine months of 2011. Excluding the effects of foreign currency translation, BEST revenue for the first nine months of 2012 increased by 35.5% over the comparable period in 2011. BEST segment GAAP EPS for the nine months ended September 30, 2012 was $0.05, compared to a loss per diluted share of ($0.04) for the nine months ended September 30, 2011. BEST segment adjusted EPS for the nine months ended September 30, 2012 was $0.06, compared to an adjusted net loss per diluted share of ($0.02) for the comparable period in 2011.Comment and Outlook Frank Laukien, President and CEO of Bruker Corporation, commented: “Despite continued softening of demand in certain markets, we are pleased with our double-digit third quarter 2012 organic revenue growth rate, which in part benefitted from our still very significant backlog. Profitability also improved in the third quarter year-over-year. As a result of our third quarter performance, we are raising our full-year 2012 revenue guidance to a range of $1.73 - $1.76 billion, and we are raising our full-year adjusted EPS guidance to $0.75 - $0.79 per diluted share.” Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including organic revenue growth, adjusted EPS, adjusted operating income, adjusted net income and adjusted operating margin, which exclude acquisition-related and restructuring and other charges. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or guidance.